Subtype
Blood Vessel Neoplasm
CI-CAN-00000567Explore in graph →
Non-malignant50 active trials4 approved drugs8 evidence items
- NCIt
- C7387
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000567Explore in graph →
Clinical trials
292 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03157167 | An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) | completed | Phase 1 | 15 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02595866 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer |
| completed |
| Phase 1 |
| 58 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 9, 2024 |
| clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03009201 | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT01495598 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00000987 | A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00001113 | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000660 | Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000725 | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 56 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000763 | A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 42 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000694 | A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 18 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000695 | Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000954 | A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 72 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 29, 2021 | clinicaltrials |
| NCT00000769 | A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT01016730 | Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2018 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00001535 | Twins Study of Gene Therapy for HIV Infection | completed | Phase 1 | 48 | National Human Genome Research Institute (NHGRI)NIH | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002153 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | completed | Phase 1 | 25 | DEKK-TEC, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002262 | A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma | completed | Phase 1 | — | University of California, San FranciscoOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002342 | A Study of Tecogalan Sodium | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Jun 5, 2025source: clinicaltrials